Vaccine breakthrough as booster shot increases Covid antibody defence by NINE times

Covid: Study on vaccine effectiveness released in UK

Sign up for FREE for the biggest new releases, reviews and tech hacks

Invalid email

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

Johnson and Johnson have announced the preliminary data following a study of 17 people. The results offer new hope for the efficacy of booster shots in fighting the pandemic. The breakthrough follows more and more .

According to Johnson and Johnson, a second dose of the J&J Janssen vaccine offers a ninefold increase in binding antibody levels.

The results were achieved after a second jab was administered six months after the first.

Binding antibodies neutralise the Covid threat by marking the coronavirus as a target for the immune system.

The increase in antibodies was much higher compared to a second shot just 28 days after the first dose.

Johnson and Johnson made the announcement following two, early-stage trials.

READ MORE: The 13 major UK towns and cities that could be underwater by 2100

Johnson and Johnson vaccine

A booster shot of the Johnson and Johnson vaccine bolsters antibody production (Image: EXPRESS)

Nurse with Johnson and Johnson vaccine

The Johnson and Johnson vaccine is a single dose jab (Image: GETTY)

Unlike the Pfizer-BioNTech vaccine, the J&J jab is a single-dose vaccine.

However, Johnson and Johnson has not released any data on whether a second dose of its vaccine increased the amount of so-called neutralising antibodies.

Neutralising antibodies protect the system by preventing the coronavirus from entering cells.

According to Dan Barouch, a Harvard vaccine researcher, the data is still being analysed.

Dr Barouch played a role in designing the J&J vaccine but was not involved in the booster study.

The news comes after Israeli researchers found a third shot of the .

Delta variant: Expert on vaccines’ impact on transmissibility

Israel and the US are among a handful of countries that have begun the rollout of booster shots.

The .

The need for more protection is all the more pressing as the Delta variant of Covid threatens new spikes of infections.

The Delta variant is more contagious and easier to transmit.

Johnson and Johnson’s studies released on Wednesday have shown an increase in binding antibodies in patients aged 18 to 55.

This response was recorded in patients over the age of 65 who were given a lower booster dose.


Sajid Javid: Booster jabs could begin in September [REPORT]

NHS ‘continues to plan’ Covid vaccine rollout for 12-year-olds [INSIGHT]

Scientists may have found the most important indicator of Covid death [STUDY]

Covid variant names listed

The Delta variant of coronavirus is more easily transmitted (Image: EXPRESS)

Man receiving the Johnson and Johnson vaccine

The Moderna and Pfizer vaccines have already been approved for booster shots (Image: GETTY)

The findings were presented on the preprint server MedRxiv ahead of publication in a peer-reviewed journal.

Earlier this month, the US Centers for Disease Control and Prevention (CDC) had approved the Pfizer and Moderna vaccines for booster shots.

The CDC is now looking for data that can lead to the approval of J&J boosters.

The CDC said: “It is likely that people who received a J&J COVID-19 vaccine will need a booster dose.

“Because the J&J/Janssen vaccine wasn’t given in the United States until 70 days after the first mRNA vaccine doses (Pfizer-BioNTech and Moderna), the data needed to make this decision aren’t available yet.”

With the data in hand, the CDC is expected to inform the public with “a timely plan for J&J/Janssen booster shots”.

A spokesman for Johnson and Johnson said the full results of the two studies will be published in a matter of weeks.

Mathai Mammen, head of research and development at J&J’s Janssen pharma division, said in a statement: “With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine.

“We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.”

William Murphy

William Murphy

Related post